| Line Item | 2026-03-31 | Y/Y |
|---|---|---|
| Net Income | -$1.7M | -203.6% |
| Line Item | 2026-03-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $2.5M | — |
| Current Assets | $5K | +3.0% |
| Total Assets | $2.5M | +3.1% |
| Current Liabilities | $330K | -83.5% |
| Total Liabilities | $1.5M | -27.5% |
| Stockholders' Equity | -$1.5M | +27.6% |
| Line Item | 2026-03-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$189K | +47.3% |
| Investing Cash Flow | $0 | — |
| Financing Cash Flow | $192K | +9.4% |
Business Overview
Piermont Valley Acquisition Corp is a blank check company formed to complete a business combination with one or more target businesses. The company signed a merger agreement on April 17, 2026 with Tigerless Health, Inc., whereby Tigerless shareholders would own a majority of the combined entity (Pubco) following closing, with contingent earn-out consideration of up to $100.0 million payable based on specified performance milestones over four years.
Forward Guidance
The company states it "intends to cause Pubco to apply to list its Class A common stock on The Nasdaq Stock Market (or another national securities exchange) in connection with the Closing, although there can be no assurance that such listing will be obtained." The Merger Agreement provides that earn-out consideration of up to $25.0 million per year may be earned if "certain operational or financial targets are met, including metrics relating to revenue or policyholder growth, gross margin improvement or systems integration milestones" over four annual earn-out periods. The document also notes: "Other than as specifically discussed herein, the rest of this Annual Report assumes that we will not consummate the Transactions with Tigerless and will seek to consummate a business combination with another target business."
Key Risk Factors
The company faces significant risks including: (1) failure to complete a business combination, as evidenced by the Nasdaq delisting in June 2024 due to missing the 36-month deadline, with an extended deadline of March 3, 2027; (2) redemption risk, with shareholders having redeemed over $242 million cumulatively across multiple extension votes, substantially reducing available capital; (3) dependence on identifying and completing a transaction with Tigerless or another target business subject to customary closing conditions and shareholder approvals; (4) execution risk on the Tigerless transaction, with a termination date of September 30, 2026 (extendable to December 31, 2026); and (5) uncertainty regarding PIPE financing commitments of at least $5.0 million, with no binding agreements currently in place.